Canaccord analyst Edward Nash downgraded Amryt Pharma to Hold from Buy with a price target of $17, down from $19, after the company agreed to be acquired by Chiesi Farmaceutici for $14.50 per ADS in cash, plus Contingent Value Rights of up to $2.50 per ADS payable if certain milestones related to Filsuvez are achieved.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AMYT:
- Amryt Pharma downgraded to Neutral from Overweight at Cantor Fitzgerald
- Chiesi Farmaceutici S.p.A. to acquire Amryt Pharma
- Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
- Amryt Pharma announces results from Phase 3 pediatric trial of lomitapide
- Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH